---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000182"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T11:38:43.979411+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Centessa presents ORX750 preclinical data; shows potential best-in-class profile for narcolepsy

## Summary
- ORX750 potently activates OX2R with EC50 of 0.11 nM and 9,800-fold selectivity over OX1R.
- Oral doses as low as 0.1 mg/kg achieved 100% wake time for ≥3 hours and suppressed cataplexy for ≥6 hours in mouse models.
- Effects on wake and cataplexy latency maintained for >14 days of dosing.
- Clinical proof-of-concept data planned for 2024; IND-enabling studies ongoing.
- Preclinical PK profile suggests high, early, and sustained brain exposure in multiple species.

## SEC filing metadata
- accession: 0001847903-23-000182
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000182/0001847903-23-000182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000182/cnta-20231025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000182
- JSON: https://secwatch.observer/filing/0001847903-23-000182.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.